The Women's Health Task Force was relaunched to address the intersection of women's health and pulmonary vascular disease. The webinar includes research presentations on sex differences and sex hormone treatments in pulmonary arterial hypertension (PAH). Studies show that this disease primarily affects women, but men have worse survival. There has been significant research on the role of sex hormones in this disparity including the phase 3 trial of anastrozole that was presented. The Women's Health Task Force aims to improve knowledge, encourage research, and optimize delivery of clinical care to women with pulmonary vascular disease, with future events planned to foster global collaboration on women's health and pulmonary hypertension.